Payment overview · 2025
General Payments
$499.16
12 reported records · 5 companies
Healthcare provider profile · identity verified
Sanjay Kumar, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PORT CHARLOTTE, FL · NPI 1669585378
Verified facts
What the public records show
CMS Open Payments records show Sanjay Kumar, MD received $499.16 in general payments during 2025 across 12 reported records.
Boston Scientific Corporation accounted for 55.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Myrbetriq by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $274.49 | 55.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $152.83 | 30.6% | 7 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $28.43 | 5.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.53 | 4.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $18.88 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $499.16 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $274.49 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $118.15 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $95.15 | 4 | 2025 |
Source payment records
|
|||||
| ECHOTIP INSIGHT Normalized: echotip insight |
Device | Cook Medical LLC | $28.43 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $24.53 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $18.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 602 | 176 |
| Atorvastatin Calcium | Atorvastatin Calcium | 364 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 311 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 285 | 78 |
| Losartan Potassium | Losartan Potassium | 212 | 62 |
| Lisinopril | Lisinopril | 190 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 182 | 55 |
| Ezetimibe | Ezetimibe | 176 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 55 |
| Metformin Hcl | Metformin Hcl | 156 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 130 | 35 |
| Allopurinol | Allopurinol | 124 | 40 |
| Simvastatin | Simvastatin | 111 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 30 |
| Gabapentin | Gabapentin | 99 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 96 | 43 |
| Omeprazole | Omeprazole | 92 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 31 |
| Jardiance | Empagliflozin | 89 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 23 |
| Trazodone Hcl | Trazodone Hcl | 85 | 26 |
| Ozempic | Semaglutide | 81 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 23 |
| Furosemide | Furosemide | 73 | 27 |
| Finasteride | Finasteride | 70 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 66 | 19 |
| Eliquis | Apixaban | 63 | 20 |
| Prednisone | Prednisone | 62 | 35 |
| Montelukast Sodium | Montelukast Sodium | 60 | 19 |
| Spironolactone | Spironolactone | 57 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 57 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 16 |
| Farxiga | Dapagliflozin Propanediol | 52 | 18 |
| Glimepiride | Glimepiride | 52 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 51 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 51 | 16 |
| Potassium Chloride | Potassium Chloride | 46 | 17 |
| Alprazolam | Alprazolam | 45 | suppressed |
| Januvia | Sitagliptin Phosphate | 45 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 44 | 16 |
| Alendronate Sodium | Alendronate Sodium | 43 | 13 |
| Atenolol | Atenolol | 43 | 13 |
| Azithromycin | Azithromycin | 40 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 39 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 39 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Celecoxib | Celecoxib | 31 | 12 |
| Pregabalin | Pregabalin | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 30 | suppressed |
| Methylprednisolone | Methylprednisolone | 30 | 23 |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 29 | 11 |
| Famotidine | Famotidine | 28 | 11 |
| Carvedilol | Carvedilol | 26 | suppressed |
| Clonazepam | Clonazepam | 26 | suppressed |
| Lovastatin | Lovastatin | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Ramipril | Ramipril | 23 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 19 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Tadalafil | Tadalafil | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $499.16 · 12 records | Boston Scientific Corporation | ECHOTIP INSIGHT, FARAPULSE, Leqembi, QULIPTA, UBRELVY, Veozah | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error